Navigation Links
Drugs for hair loss and BPH may result in loss of libido, ED in men
Date:1/11/2011

(Boston) Researchers from Boston University School of Medicine (BUSM), in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors (5a-RIs), while improving urinary symptoms in patients with benign prostatic hyperplasia (BPH) and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction (ED), ejaculatory dysfunction and potential depression. These findings, which currently appear on-line in Journal of Sexual Medicine, suggest that extreme caution should be exercised prior to prescribing 5a-RIs therapy to patients for hair growth or for BPH symptoms.

5a-RIs, finasteride (Propecia) and dutasteride, have been approved for treatment of lower urinary tract symptoms, due to BPH, with marked clinical efficacy. Finasteride is also approved for treatment of hair loss (androgenetic alopecia). Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse effects on sexual function, gynecomastia, depression, and quality of life remains ill-defined.

In order to determine the potential extent of this problem, the researchers examined the data reported in various clinical studies concerning the side effects of finasteride and dutasteride. After a review of the literature the researchers found that in a subset of men, prolonged adverse effects on sexual function such as erectile dysfunction and diminished libido were reported, raising the possibility of a causal relationship.

According to the researchers, the adverse side effects of 5a-RIs on sexual function, gynecomastia and the impact on the overall health have received minimal attention. However, in some patients, these side effects are persistent with regard to sexual function and with an emotional toll including decreased quality of life.

"The potential widespread use of 5a-RIs for treatment of BPH, prostate cancer and male pattern hair loss may produce undesirable adverse side effects on overall health and in particular, vascular health and sexual function in a subgroup of susceptible patients, " said lead author Abdulmaged M. Traish, MBA, PhD, a professor of biochemistry and professor of Urology at BUSM. "Furthermore, treatment of hair loss, a benign condition with 5a-RIs may produce persistent side effects in a number of young patients," he added.

"Honest and open discussion with patients to educate them on these serious issues must be pursued prior to commencing therapy because, in some patients, these adverse effects are persistent and may be prolonged and patients do not recover well after discontinuation from drug use," cautioned Traish.

The researchers believe additional clinical and preclinical studies are warranted to determine the reason for why some of these adverse effects persist in some individuals.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
2. Studies Decipher How Anti-Smoking Drugs Work
3. Structure of key molecule in immune system provides clues for designing drugs
4. Heartburn Drugs May Raise Pneumonia Risk
5. Trio of drugs may combat triple negative breast cancer
6. Drugs are safe, active in patients normally ineligible for clinical trial
7. Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
8. Economist honored for study on impact of new cancer drugs on life expectancy
9. FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer
10. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
11. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... Cary, NC (PRWEB) , ... January 15, 2017 ... ... to announce that Albertsons Companies has achieved accreditation for its specialty care services. ... accreditation and its own in-house specialty care service for pharmacy patients. , Accreditation ...
(Date:1/15/2017)... ... 14, 2017 , ... Wondering where to go this Valentine's Day? Well, there ... for a romantic, lobster feast in the comfort of your own home. Lobster Gram ... dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living brand Moody ... activated charcoal products. With more and more people opting to go organic in ... how they cater to specific needs. , Moody Zook focused particularly on their ...
(Date:1/14/2017)... ... 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows users ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume ... from one clip to the next. , To use “Cut-Out First” presets, choose ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... A January ... top five procedures for 2017 according to the publication, with an emphasis on some ... Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., who is known more casually to his patients and ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... , Jan. 16, 2017 The global pacemaker ... 2025, according to a new report by Grand View ... with the availability of medical coverage is a key ... addition, technological enhancements in these devices are supporting the ... Diseases (CVDs) is a high-impact growth rendering driver for ...
(Date:1/16/2017)... HOUSTON , Jan. 16, 2017 ... of Potts Law Firm, was recently appointed Liaison Counsel ... Proceedings (JCCP) for all Xarelto cases. In this role, ... plaintiff parties and will actively assist the Court and ... with Milstein Adelman Jackson Fairchild & ...
Breaking Medicine Technology: